Rezolute, Inc. (identified in the filing as AntriaBio, Inc.) — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017, with fiscal 2016 comparative figures. The supplied filing does not report a 2016 Q4 period and is filed under AntriaBio, Inc.; investors should confirm the entity and period intended by the request.
Business context and development
AntriaBio was a clinical-stage biopharmaceutical company with no commercial products or revenue. Its lead candidate, AB101, is a proposed once-weekly basal insulin. The company filed an IND in June 2017; its first Phase 1 patient was dosed in July 2017, after fiscal year-end. AB301, a proposed once-weekly insulin/GLP-1 combination, remained in preclinical development. In August 2017, the company licensed ActiveSite’s plasma kallikrein inhibitor program, targeting diabetic macular edema and other conditions.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.09 million | $9.45 million |
| General and administrative expense | $8.23 million | $5.50 million |
| Net loss | $20.28 million | $14.94 million |
| Net loss attributable to common stock | $23.68 million | $20.91 million |
| Net cash used in operations | $13.31 million | $10.49 million |
| Cash at year-end | $4.49 million | $4.06 million |
With no revenue, operating margins are not meaningful. The common-stock loss in 2017 includes a $3.41 million deemed dividend from warrant modifications; 2016 included a $5.97 million cumulative preferred-stock dividend. The company reported $4.93 million in current assets, $1.77 million in current liabilities, and $3.16 million in working capital at June 30, 2017. Total liabilities were $2.10 million, including $10,000 of convertible notes; the filing says the remaining notes had matured and were due. Net cash from financing was $13.93 million in FY2017, largely from equity issuance. No off-balance-sheet arrangements were reported.
Changes, outlook, risks, and unusual items
- Net loss increased by $5.34 million year over year. R&D expense rose mainly with higher staffing and AB101 manufacturing and clinical-study costs; G&A increased with stock-based compensation, professional fees, and rent. FY2017 included approximately $1.2 million of compensation expense related to cancelled options.
- Management targeted raising at least $15 million to fund operations through calendar 2018, including AB101 studies, pipeline work, and overhead. It reported raising approximately $13 million during calendar 2017. These are management expectations, not assured funding; the filing says cash resources are inadequate to sustain planned operations for more than one year from issuance.
- The auditor included a going-concern explanatory paragraph, citing recurring losses and inadequate liquidity. Management warned that failure to obtain financing could require delaying, reducing, or discontinuing programs or curtailing operations. Progress and financing depend substantially on AB101 study results.
- AB101 Phase 1 results were expected as early as Q4 2017; management planned subsequent Phase 2 work. The company estimated that more than $300 million would be needed to fund AB101 through potential approval and expected to seek a larger pharmaceutical partner for later development.
- The ActiveSite license carries a $750,000 upfront payment, milestone payments of $1 million to $10 million, and 2% royalties on applicable product sales. The filing describes the agreement as entered into after year-end.
- Lease obligations totaled $3.32 million before $457,743 of expected sublease income, or $2.87 million net. The shareholder derivative litigation was settled and court-approved; a separate proposed legal-fee settlement called for two $125,000 payments, subject to court approval.
- Disclosure controls and internal control over financial reporting were not effective at year-end because of a material weakness involving inadequate segregation of duties, potential override by the chief accounting officer, and insufficient review of complex accounting. Management had begun evaluating corrective procedures but did not assure full remediation.
- Key risks include financing and dilution, clinical and regulatory failure, manufacturing and supplier dependence, competition, intellectual-property protection, product liability, limited OTC trading liquidity, and the absence of commercial revenue. The company also reported 32.8 million warrants outstanding and 21.3 million outstanding options at June 30, 2017.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the filing is for AntriaBio, Inc., fiscal year ended June 30, 2017, rather than a 2016 Q4 report.
- Check subsequent financing actually received, cash runway, and whether the targeted additional $15 million was raised on acceptable terms.
- Review AB101 Phase 1 results and subsequent clinical progress, and whether a development partner was secured.
- Verify payment and continuing obligations under the ActiveSite license, including milestones and royalties, and approval/payment status of the legal-fee settlement.
- Track remediation of the material weakness and assess potential dilution from options, warrants, and future equity financing.